



## Apathy as a Risky Neuropsychiatric Syndrome of Progression From Normal Aging to Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis

Zili Fan<sup>1,2</sup>, Luchun Wang<sup>1,2</sup>, Haifeng Zhang<sup>1,2</sup>, Xiaozhen Lv<sup>1,2</sup>, Lihui Tu<sup>1,2</sup>, Ming Zhang<sup>1,3</sup>, Ying Zhang<sup>1,2</sup>, Caihua Yan<sup>4</sup>, Xin Yu<sup>1,2\*</sup> and Huali Wang<sup>1,2\*</sup>

#### **OPEN ACCESS**

#### Edited by:

Jenni Lehtisalo, University of Eastern Finland, Finland

#### Reviewed by:

Luca Cravello, ASST Rhodense, Italy Angelo Bianchetti, Istituto Clinico S.Anna - Gruppo San Donato, Italy

#### \*Correspondence:

Xin Yu yuxin@bjmu.edu.cn Huali Wang huali\_wang@bjmu.edu.cn

#### Specialty section:

This article was submitted to Aging Psychiatry, a section of the journal Frontiers in Psychiatry

Received: 09 October 2021 Accepted: 22 November 2021 Published: 20 December 2021

#### Citation:

Fan Z, Wang L, Zhang H, Lv X, Tu L, Zhang M, Zhang Y, Yan C, Yu X and Wang H (2021) Apathy as a Risky Neuropsychiatric Syndrome of Progression From Normal Aging to Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. Front. Psychiatry 12:792168. doi: 10.3389/fpsyt.2021.792168 <sup>1</sup> Beijing Dementia Key Lab, Dementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing, China, <sup>2</sup> NHC Key Laboratory of Mental Health, National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Peking University, Beijing, China, <sup>3</sup> Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, <sup>4</sup> Department of Psychiatry, The First Hospital of Hebei Medical University, Shijiazhuang, China

**Background:** Apathy has been suggested as a potential predictor of mild cognitive impairment (MCI) progression to dementia. Whether it might predict the transition from normal cognitive function to cognitive impairment has been less studied. The current study aimed to provide a comprehensive summary of the evidence on the association between apathy and the transition from normal cognitive function to cognitive impairment.

**Methods:** We searched the PubMed, Embase, and Web of Science databases for longitudinal prospective cohort studies that evaluated apathy at baseline in the cognitively normal population and had cognitive impairment as the outcome. Random effects models were used, and heterogeneity was explored with stratification. The stability of the synthesized result was indicated using sensitivity analysis by excluding one study each time and recalculating the overall effect.

**Results:** Ten studies comprising 26,195 participants were included. Apathy status was available for 22,101 participants. Apathy was present in 1,803 of 22,101 participants (8.16%). Follow-up ranged from 1 to 13 years. The combined odds ratio (OR) of cognitive impairment for patients with apathy was 2.07 (95% Cl: 1.43–2.99;  $I^2 = 86\%$ ), and the combined hazard ratio was 2.70 (95% Cl: 1.38–5.27;  $I^2 = 94\%$ ). The OR meta-analyses for different conversion outcomes were MCI (OR = 3.38, 95% Cl: 1.57–7.28;  $I^2 = 71\%$ ), cognitive decline (OR = 1.27, 95% Cl: 0.81–2.00;  $I^2 = 64\%$ ) and dementia (OR = 2.12, 95% Cl: 1.32–3.41;  $I^2 = 86\%$ ). Subgroup analysis suggested that the association between apathy and cognitive impairment changed with age, depression adjustments, apathy measurement, and follow-up time.

1

**Conclusions:** Apathy was associated with a greater than 2-fold increased risk of progression to cognitive impairment in the cognitively normal population. Future interventions targeting apathy management in the general population may reduce the risk of cognitive impairment.

Keywords: apathy, normal aging, mild cognitive impairment, dementia, neuropsychiatric syndrome

## INTRODUCTION

Dementia has been considered a public health priority, and there is growing interest in identifying predictive factors of cognitive impairment. Increasing evidence suggests that neuropsychiatric symptoms (NPS) have prognostic value in predicting accelerated disease progression and functional decline (1, 2). NPS refers to disturbances of behavior-, emotion-, and thought-related neurodegenerative diseases (3). In many individuals, the first symptoms of dementia might be NPS rather than a change in cognitive function. Thus, NPS might identify cognitively healthy persons at risk of dementia for prevention trials (4). As one of the most common NPSs, the prevalence of apathy was 4.8% in the cognitively normal (CN) population (5).

Apathy has been defined as loss of motivation, characterized by diminished goal-oriented behavior and cognition and reduced emotional expression (6). Apathy is known to contribute to caregiver burden significantly and has negative implications for activities of daily living among those with dementia (7, 8). Recently, a meta-analysis reported that apathy was associated with an approximately 2-fold increased risk of dementia among those visiting memory clinics (9). The association between apathy and dementia weakened with increasing cognitive impairment. This meta-analysis mainly included samples with mild cognitive impairment (MCI) rather than the CN population. The apathy that could predict the CNcognitive impairment transition was not identical to that of the MCI-dementia transition. For example, one study among the general population showed that apathy at baseline did not have value in predicting the progression from CN to dementia (10).

Previous clinical studies of the associations between apathy and cognitive impairment among CN populations are also inconsistent. For example, one study showed that apathy failed to predict MCI in community-dwelling older adults. However, in sensitivity analyses of MCI subtypes, apathy was associated with non-amnestic MCI but not amnestic MCI (11). In another community-based study, apathy was associated with an approximately 2.3-fold increased risk of MCI (12). The variability of results between studies might be partly explained by methodological differences in the apathy measurement, the lack of adjustment for depression, or the follow-up time.

The inconsistency in results regarding apathy as a predictor of cognitive decline among study findings in CN populations hinders progress in research on apathy in dementia. Furthermore, no systematic review or meta-analysis has examined aspects of apathy as predictors of cognitive decline among CN populations. Therefore, the current

study aims to provide a comprehensive summary of the evidence on the association between apathy and the transition to cognitive impairment, including MCI and dementia, among those in the CN population and to further explore the subgroup differences via a meta-analysis of prospective longitudinal studies.

## METHODS

This meta-analysis is reported in line with the PRISMA statement. The PRISMA checklist is provided in the **Supplementary Material 1**.

#### **Search Strategy and Study Selection**

We searched for all cohort studies reporting associations between apathy and the incidence of cognitive impairment published in PubMed, Embase, and Web of Science databases from their inception to August 27, 2020. Briefly, the search strategy included the following terms: (apathy or neuropsychiatric symptoms AND (dementia or cognitive impairment or Alzheimer disease) AND (cohort study OR longitudinal study OR risk) using both medical subject headings and abstract searches (**Supplementary Table 2**). In addition, articles were included if they (1) involved unselected general populations or populations with normal cognitive function at baseline; (2) utilized a longitudinal prospective cohort study design; (3) reported data regarding the association between apathy and incident cognitive impairment; and (4) were peer-reviewed articles.

Studies were excluded if they (a) used a cross-sectional design; (b) were published in an abstract format; (c) included participants with cognitive impairment at baseline, or (d) were not published in English. References of relevant articles and systematic reviews were also searched for additional studies. References were compiled using Endnote x9, with duplicates removed using this software. The references identified from the literature search were screened based on the titles and abstracts by one reviewer (ZF) to identify potentially relevant articles. Duplicate and ineligible studies were removed.

### **Data Extraction and Quality Assessment**

Two reviewers (ZF and LW) independently extracted the data and evaluated the quality of the included studies. The inclusion or exclusion of studies was decided based on consensus. Any indecision about study inclusion was discussed with a third reviewer (HW). We extracted the following information from each study included in the meta-analysis: sample settings, sample



size, average or median follow-up duration, the number of cognitive impairment cases in the apathy and non-apathy groups, percentage of women, age of participants, the instrument used to measure apathy, diagnostic criteria for cognitive impairment, covariates included in the adjusted models, and adjusted odds ratio (OR)/hazard ratio (HR) estimates. We used the Newcastle-Ottawa Scale (NOS) to analyze the risk of study bias (13), a nine-point scale used to evaluate the risk of bias of a given cohort study based on three criteria: population selection, comparability, and outcome. Higher scores on the NOS indicated a lower risk of bias.

## **Data Analysis**

For the meta-analyses, we considered ORs as the main effect size. Studies reporting HRs were analyzed separately. The HRs adjusted for confounders in the final model were included in the meta-analysis. Studies with two follow-up times were included in the OR meta-analysis twice. The HR meta-analysis did not include studies reporting HRs by separating the association according to whether regional brain glucose hypometabolism was present rather than the whole sample. A random-effects model was used to address both of the study objectives because of heterogeneity between studies. Heterogeneity was assessed using  $I^2$  statistics.

Subgroup analyses based on various factors were performed to explore their impact on heterogeneity: sample type, age, percent of women in the sample, duration of the follow-up time, apathy measurement, depression adjustment, APOE status adjustment, diagnostic criteria of the outcome, and different conversion outcomes. In addition, sensitivity analysis to inspect the influence of a single study on the overall result was conducted by omitting studies one by one. Finally, publication bias was assessed by funnel plots and Egger's test. All statistical analyses were performed with STATA statistical software 15.1 and Review Manager 5.3.

## RESULTS

# Search Results and Characteristics of the Included Studies

From 5,549 titles and abstracts, ten studies were included in the final synthesis (**Figure 1**) (1, 9–12, 14–18). Details regarding the study characteristics of the included studies are presented in **Table 1**. Among the ten studies comprising 26,195 participants, apathy was diagnosed in 1,803 of 22,101 participants (8.16%). The median population sample size was 1,408 (range: 457–12,452). The median duration of follow-up was 4.3 years (range: 1 and 13 years). The median/mean age was 72.8 years (range: 65.56–79.3), excluding one study that did not report the mean or median age (14), and the median percentage of women was 61.6% (range: 47.2–63.7%).

## **Risk of Bias Assessment**

The risk of bias assessment is shown in **Supplementary Figure 1** of the Supplemental documents. Based on total NOS scores, nine studies had a quality score of 7–9, indicating a low risk of bias, and 1 study that included two follow-up times had quality scores of 4–6, indicating a medium risk of bias. The worst scoring categories were outcome assessment, outcome exclusion, and follow-up availability.

## Meta-Analysis of Cognitive Impairment Incidence

The overall estimate for incident cognitive impairment is shown in Figure 2. The pooled estimate showed that apathetic individuals had a significantly higher risk of developing cognitive impairment than individuals who did not (OR = 2.07, 95% CI: 1.43–2.99). The plot shows high levels of heterogeneity ( $I^2 =$ 86%, p < 0.001). Pooling the maximally adjusted HR estimates had similar results, with a combined HR of 2.70 (95% CI: 1.38-5.27) and considerable heterogeneity ( $I^2 = 94\%$ ). After excluding studies one by one from the analysis, the pooled OR slightly changed but remained statistically significant, from 1.85 (95% CI: 1.33-2.57) to 2.29 (95% CI: 1.61-3.25) (Supplementary Figure 2 in the Supplementary documents). The sensitivity analysis for HRs showed similar results, which remained statistically significant, from 2.03 (95% CI: 1.11-3.70) to 3.34 (95% CI: 1.81-6.19) (Supplementary Figure 3 in the supplemental documents). It clearly showed no significant impact of any study on the overall combined results, which remained statistically significant.

#### TABLE 1 | Characteristics of the studies included in the meta-analysis.

References	Population setting	Sample size	Average or median follow- up (year)	Age, mean (SD) or median (year)	Female, No. (%)	Apathy measure	Outcome	Criteria	Reported association or cognitive impairment incidence	Adjustments	NOS
Clarke et al. (15)	Community- dwelling older adults	1,136	1	65.56 (8.79)	700 (61.6)	GHQ (≥6.5)	Cognitive decline	3-point reduction in MMSE scores between baseline and follow-up	OR: 1.65 (1.06–2.60)	Age, sex, education, race, and depression	5
Clarke et al. (15)	Community- dwelling older adults	1,136	13	65.56 (8.79)	700 (61.6)	GHQ (≥6.5)	Cognitive decline	3-point reduction in MMSE scores between baseline and follow-up	OR: 1.04 (0.76–1.44)	Age, sex, education, race, and depression	6
Krell-Roesch et al. (1)	Community- dwelling older adults	1,363	4.8	71.1	644 (47.2)	NPI-Q	MCI	revised Mayo Clinic criteria	HR: FDG-PET-/apathy+: 6.85 (3.36, 14.0); FDG-PET+/apathy+: 5.26 (2.48, 11.1); To MCI: 18 convertors in 42 with apathy; 155 convertors in 1,209 without apathy	Age, sex, education, and APOE £4 status, medical comorbidity and antidepressant medication intake	9
Acosta et al. (10)	Community- dwelling older adults	1,355	3	73.2 (0.17)	64.3 (871)	NPI-Q	Dementia	DSM-IV	RR: 1.4 (0.9–2.3); To dementia: 16 convertors in 121 with apathy; 113 convertors in 1234 without apathy	Age, gender, level of educational attainment, and MCI	8
van der Linde et al. (14)	Population in rural and urban areas	457	2	197 (29.4)#	348 (54.5)	GMS- AGECAT	Dementia	DSM-III	To dementia: 1 convertor in 40 with apathy; 4 convertors in 417 without apathy	Age, sex, education, social class, MMSE, subjective and objective memory and ADL	8
Liew (16)	Clinical samples	12,452	4.7	72	7938 (63.7)	NPI-Q	Dementia	DSM-IV	To dementia: 68 convertors in 574 with apathy; 656 convertors in 11,878 without apathy	Age, sex, ethnicity, education, APOE e4 status and use of antidepressants	9
Burke et al. (17)	Database of memory clinics	1567	4	71.2 (10.9)	988 (63)	NPI-Q	AD	NINCDS	HR: 9.51 (5.23-17.31); 193 convertors in 297 with apathy; 372 convertors in 1,144 without apathy	Sex, age, race, APOE ɛ4, Hispanic origin, family history	8
Geda et al. (12)	Community- dwelling older adults	1,408	5	79.3	704 (50.0)	NPI-Q	MCI, aMCI, non-MCI	Mayo Clinic criteria	HR: 2.26 (1.49–3.41); To dementia: 25 convertors in 57 with apathy; 339 convertors in 1,351 without apathy	Age, sex, education and medical comorbidity	9

Fan et al.

(Continued)

Apathy Predict Incident Cognitive Impairment

#### TABLE 1 | Continued

References	Population setting	Sample size	Average or median follow- up (year)	Age, mean (SD) or median (year)	Female, No. (%)	Apathy measure	Outcome	Criteria	Reported association or cognitive impairment incidence	Adjustments	NOS
Van Dalen et al. (9)	Community- dwelling older adults	3,499	6	74.3 (2.5)	1899 (54.3)	GDS-3A	Dementia	DSM-IV	HR: 1.21 (1.06–1.40); isolate apathy: 1.20 (1.00-1.45); To dementia: 56 convertors in 672 with apathy symptom; 176 convertors in 2,755 without apathy	Age, sex, MMSE, disability, and history of stroke or cardiovascular disease	9
Ceïde et al. (11)	Community- dwelling older adults	542	13.6 months	76.0 (6.7)	299 (55.2)	GDS-3A	MCI, aMCI, non-MCI	1.5 SD below the RBANS	HR: 1.64 (0.99–2.71)	Adjusted for age, education, baseline global cognition (RBANS), and depressive symptoms	7
Masters et al. (18)	Clinical samples	2,416	4.3*	77.8 (8.9)*	749 (61.5)*	NPI-Q	AD	CDR	HR: 3.81 (2.79–5.2)	Adjusted for age, sex, education, race, and APO e4 status	9

\*those who developed CDR > 0; <sup>#</sup>Only a proportion of participants 75 years and older was available. aMCl, amnestic mild cognitive impairment; CDR, Clinical Dementia Rating; GDS-3A, Geriatric Depression Scale 3 Apathyrelated subitems; GMS-AGECAT, Geriatric Mental State Automated Geriatric Examination for Computer Assisted Taxonomy; MCl, mild cognitive impairment; MMSE, Mini-Mental State Examination; NPI-Q, Neuropsychiatric Inventory Questionnaire for clinical informants; GHQ, the 20-item General Health Questionnaire.

Frontiers in Psychiatry | www.frontiersin.org

				Odds Ratio	Odds Ratio
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI	IV. Random, 95% Cl
MCI					
Geda et al.2014	0.8468	0.2742	11.1%	2.33 [1.36, 3.99]	
Krell Roesch et al.2020	1.6292	0.3235	10.2%	5.10 [2.71, 9.61]	
Subtotal (95% CI)			21.3%	3.38 [1.57, 7.28]	
Heterogeneity: Tau² = 0.22; Test for overall effect: Z = 3	Chi <sup>2</sup> = 3.40, df = 1 .12 (P = 0.002)	(P = 0.07	7); I² = 71%	6	
Dementia					
Acosta et al.2018	0.4132	0.2859	10.9%	1.51 [0.86, 2.65]	
Burke et al.2016	1.3484	0.137	13.5%	3.85 [2.94, 5.04]	
Tau Ming Liew.2020	0.8324	0.1353	13.5%	2.30 [1.76, 3.00]	
Van Dalen et al.2018	0.2868	0.1598	13.2%	1.33 [0.97, 1.82]	
Van der Linde et al, 2013	0.9736	1.1305	2.3%	2.65 [0.29, 24.27]	
Subtotal (95% CI)			53.5%	2.12 [1.32, 3.41]	
Heterogeneity: Tau² = 0.21; Test for overall effect: Z = 3	Chi <sup>2</sup> = 28.00, df = 4 .09 (P = 0.002)	↓ (P < 0.0	0001); l² =	86%	
Cognitive decline					
Clarke et al. 2010(1)	0.5008	0.2258	12.0%	1.65 [1.06, 2.57]	
Clarke et al. 2010(2)	0.0392	0.16	13.2%	1.04 [0.76, 1.42]	
Subtotal (95% Cl)			25.2%	1.27 [0.81, 2.00]	-
	$(n)^{2} = 2/8$ of $= 1$	(P = 0.10)	); 1* = 64%	6	
Test for overall effect: $Z = 1$	.06 (P = 0.29)				
Test for overall effect: Z = 1	.06 (P = 0.29)		100.0%	2.07 [1.43, 2.99]	•
Test for overall effect: $Z = 1$ Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: $Z = 3$	Chi <sup>2</sup> = 57.43, df = $\xi$ .85 (P = 0.0001)	3 (P < 0.0	<b>100.0%</b> 00001); I <sup>2</sup> =	2.07 [1.43, 2.99] = 86%	
Test for overall effect: $Z = 1$ Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: $Z = 3$ Test for subaroup difference	Chi <sup>2</sup> = 57.43, df = $\xi$ .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33, df =	3 (P < 0.0 2 (P = 0	<b>100.0%</b> 00001); l <sup>2</sup> = .07). l <sup>2</sup> = 6	<b>2.07 [1.43, 2.99]</b> = 86% 2.5%	0.05 0.2 1 5 20 Favours [NCI] Favours [CI]
Test for overall effect: Z = 1 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for suboroup difference	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df =	3 (P < 0.0 2 (P = 0	<b>100.0%</b> 00001); l <sup>2</sup> = .07). l <sup>2</sup> = 6	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for subaroup difference Study or Subgroup	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = og[Hazard Ratio]	8 (P < 0.0 2 (P = 0 <b>SE</b>	<b>100.0%</b> 00001); I <sup>2</sup> = .07). I <sup>2</sup> = 6 <u>Weight</u>	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV, Random, 95% Cl	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 1 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for subaroup difference <u>Study or Subgroup</u>	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = $00000000000000000000000000000000000$	3 (P < 0.0 2 (P = 0 <u>SE</u>	<b>100.0%</b> )0001); l <sup>2</sup> = .07). l <sup>2</sup> = 6 <u>Weight</u>	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV, Random, 95% Cl	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 1 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for subaroup difference Study or Subgroup I MCI <sup></sup> Ceïde et al. 2020	$Chi^2 = 57.43, df = 8$ .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = og[Hazard Ratio] 0.4947	8 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575	<b>100.0%</b> 00001); I <sup>2</sup> = .07). I <sup>2</sup> = 6 <u>Weight</u> 19.3%	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio _IV, Random, 95% CI 1.64 [0.99, 2.72]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI
Test for overall effect: Z = 1         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Test for overall effect: Z = 3         Test for subaroup difference         Study or Subgroup         MCI         Ceïde et al. 2020         Geda et al.2014	$Chi^{2} = 57.43, df = 8$ $.85 (P = 0.0001)$ $es: Chi^{2} = 5.33. df =$ $og[Hazard Ratio]$ $0.4947$ $0.8127$	3 (P < 0.0 2 (P = 0) SE 0.2575 0.2112	<b>100.0%</b> 00001); I <sup>2</sup> = 07). I <sup>2</sup> = 6 <u>Weight</u> 19.3% 20.1%	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% CI 1.64 [0.99, 2.72] 2.25 [1.49, 3.41]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random, 95% CI
Test for overall effect: Z = 1         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Test for overall effect: Z = 3         Test for subgroup difference         Study or Subgroup         MCI         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)	$Chi^{2} = 57.43, df = 8$ $.85 (P = 0.0001)$ es: Chi <sup>2</sup> = 5.33. df = $og[Hazard Ratio]$ $0.4947$ $0.8127$	8 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575 0.2112	<b>100.0%</b> 00001); l <sup>2</sup> = 07). l <sup>2</sup> = 6 <u>Weight</u> 19.3% 20.1% <b>39.4%</b>	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% CI 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random. 95% CI
Test for overall effect: Z = 1         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Test for overall effect: Z = 3         Test for subaroup difference         Study or Subgroup         MCI         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.00	Chi <sup>2</sup> = 57.43, df = 6 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = og[Hazard Ratio] 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df =	8 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575 0.2112 1 (P = 0.	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% Cl 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random. 95% CI
Test for overall effect: Z = 1         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Test for overall effect: Z = 3         Test for subaroup difference         Study or Subgroup         MCI         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.00         Test for overall effect: Z = 3	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001)	3 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575 0.2112 1 (P = 0.	<b>100.0%</b> 00001);   <sup>2</sup> = 6 07).   <sup>2</sup> = 6 Weight 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% CI 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] %	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI
Test for overall effect: Z = 1         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Test for overall effect: Z = 3         Test for subaroup difference         Study or Subgroup         MCI         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.00         Test for overall effect: Z =	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001)	3 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575 0.2112 1 (P = 0.	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% CI 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random. 95% CI
Test for overall effect: Z = 1         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Test for overall effect: Z = 3         Test for suboroup difference         Study or Subgroup         MCI         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.00         Test for overall effect: Z =         Dementia         Burke et al.2016	Chi <sup>2</sup> = 57.43, df = 6 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = og[Hazard Ratio] 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528	3 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575 0.2112 1 (P = 0. 0.3053	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0 18.5%	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% CI 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] %	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random, 95% CI
Test for overall effect: Z = 1 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for subaroub difference Study or Subgroup I MCI <sup>-</sup> Ceïde et al. 2020 Geda et al.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00 Test for overall effect: Z = Dementia Burke et al.2016 Masters et.al.2015	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528 1.3376	3 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575 0.2112 1 (P = 0. 0.3053 0.159	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0 18.5% 20.7%	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% Cl 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] %	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random, 95% CI
Feelogeneity: Tau <sup>2</sup> = 0.07,         Fest for overall effect: Z = 1         Fotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Fest for overall effect: Z = 3         Fest for subaroup difference         Study or Subgroup         MCI         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.00         Test for overall effect: Z = 3         Dementia         Burke et al.2016         Masters et.al.2015         Van Dalen et al.2018	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528 1.3376 0.1858	8 (P < 0.0 2 (P = 0 <u>SE</u> 0.2575 0.2112 1 (P = 0. 0.3053 0.159 0.0948	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0 18.5% 20.7% 21.4%	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV. Random, 95% Cl 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] % 9.51 [5.23, 17.31] 3.81 [2.79, 5.20] 1.20 [1.00, 1.45]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random. 95% CI
Test for overall effect: Z = 1 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for subaroup difference Study or Subgroup I MCI - Ceïde et al. 2020 Geda et al.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00 Test for overall effect: Z = Dementia Burke et al.2016 Masters et.al.2015 Van Dalen et al.2018 Subtotal (95% CI)	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528 1.3376 0.1858	8 (P < 0.0 2 (P = 0 <b>SE</b> 0.2575 0.2112 1 (P = 0. 0.3053 0.159 0.0948	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0 18.5% 20.7% 21.4% <b>60.6%</b>	2.07 [1.43, 2.99] = 86% 2.5% Hazard Ratio IV, Random, 95% CI 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] % 9.51 [5.23, 17.31] 3.81 [2.79, 5.20] 1.20 [1.00, 1.45] 3.42 [1.13, 10.32]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV. Random. 95% CI
Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Fest for overall effect: Z = 3         Fost for subgroup difference         Study or Subgroup I         MCI         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.00         Test for overall effect: Z =         Dementia         Burke et al.2016         Masters et.al.2015         Van Dalen et al.2018         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.9         Test for overall effect: Z =	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.29) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528 1.3376 0.1858 1; Chi <sup>2</sup> = 69.91, df = 2.18 (P = 0.03)	8 (P < 0.0 2 (P = 0 <b>SE</b> 0.2575 0.2112 1 (P = 0. 0.3053 0.159 0.0948 = 2 (P < 0	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0 18.5% 20.7% 21.4% <b>60.6%</b> 0.00001);	2.07 [1.43, 2.99] = 86% 22.5% Hazard Ratio IV. Random, 95% Cl 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] % 9.51 [5.23, 17.31] 3.81 [2.79, 5.20] 1.20 [1.00, 1.45] 3.42 [1.13, 10.32] I <sup>2</sup> = 97%	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.07, Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for suboroup difference Study or Subgroup I MCI - Ceïde et al. 2020 Geda et al.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00 Test for overall effect: Z = Dementia Burke et al.2016 Masters et.al.2015 Van Dalen et al.2018 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.9 Test for overall effect: Z = Total (95% CI)	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528 1.3376 0.1858 1; Chi <sup>2</sup> = 69.91, df = 2.18 (P = 0.03)	<pre>3 (P &lt; 0.0 2 (P = 0 SE 0.2575 0.2112 1 (P = 0. 0.3053 0.159 0.0948 = 2 (P &lt; 0</pre>	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0 18.5% 20.7% 21.4% <b>60.6%</b> 0.00001); <b>100.0%</b>	2.07 [1.43, 2.99] = 86% 22.5% Hazard Ratio IV, Random, 95% Cl 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] % 9.51 [5.23, 17.31] 3.81 [2.79, 5.20] 1.20 [1.00, 1.45] 3.42 [1.13, 10.32] I <sup>2</sup> = 97% 2.70 [1.38, 5.27]	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 1 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; Test for overall effect: Z = 3 Test for suboroup difference Study or Subgroup I MCI <sup>-</sup> Ceïde et al. 2020 Geda et al.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00 Test for overall effect: Z = Dementia Burke et al.2016 Masters et.al.2015 Van Dalen et al.2018 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.9 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.5	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.29) Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528 1.3376 0.1858 1; Chi <sup>2</sup> = 69.91, df = 2.18 (P = 0.03) 4: Chi <sup>2</sup> = 71.02 df =	3 (P < 0.0 2 (P = 0) SE 0.2575 0.2112 1 (P = 0. 0.3053 0.159 0.0948 = 2 (P < 0 = 4 (P < 0)	<b>100.0%</b> 00001);   <sup>2</sup> = 6 <b>Weight</b> 19.3% 20.1% <b>39.4%</b> 34);   <sup>2</sup> = 0 18.5% 20.7% 21.4% <b>60.6%</b> 0.00001); <b>100.0%</b>	2.07 [1.43, 2.99] = 86% 22.5% Hazard Ratio IV. Random, 95% Cl 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] % 9.51 [5.23, 17.31] 3.81 [2.79, 5.20] 1.20 [1.00, 1.45] 3.42 [1.13, 10.32] I <sup>2</sup> = 97% 2.70 [1.38, 5.27] I <sup>2</sup> = 94%	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI
Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.25;         Fest for overall effect: Z = 3         Fost for overall effect: Z = 3         Fest for overall effect: Z = 3         Fest for overall effect: Z = 3         Fest for suboroup difference         Study or Subgroup       I         MCI       -         Ceïde et al. 2020         Geda et al.2014         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.00         Test for overall effect: Z =         Dementia         Burke et al.2016         Masters et.al.2015         Van Dalen et al.2018         Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.9         Test for overall effect: Z =         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = 0.5-         Test for overall effect: Z =	Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.29) Chi <sup>2</sup> = 57.43, df = 8 .85 (P = 0.0001) es: Chi <sup>2</sup> = 5.33. df = <b>og[Hazard Ratio]</b> 0.4947 0.8127 0; Chi <sup>2</sup> = 0.91, df = 4.19 (P < 0.0001) 2.2528 1.3376 0.1858 1; Chi <sup>2</sup> = 69.91, df = 2.18 (P = 0.03) 4; Chi <sup>2</sup> = 71.02, df = 2.91 (P = 0.004)	3 (P < 0.0 2 (P = 0) <b>SE</b> 0.2575 0.2112 1 (P = 0. 0.3053 0.159 0.0948 = 2 (P < 0 = 4 (P < 0)	100.0% 00001);   <sup>2</sup> = 07).   <sup>2</sup> = 6 Weight 19.3% 20.1% 39.4% 34);   <sup>2</sup> = 0 18.5% 20.7% 21.4% 60.6% 0.00001); 100.0% 0.00001);	2.07 [1.43, 2.99] = 86% 22.5% Hazard Ratio IV. Random, 95% CI 1.64 [0.99, 2.72] 2.25 [1.49, 3.41] 1.98 [1.44, 2.73] % 9.51 [5.23, 17.31] 3.81 [2.79, 5.20] 1.20 [1.00, 1.45] 3.42 [1.13, 10.32] I <sup>2</sup> = 97% 2.70 [1.38, 5.27] I <sup>2</sup> = 94%	0.05 0.2 1 5 20 Favours [NCI] Favours [CI] Hazard Ratio IV, Random, 95% CI

#### **Subgroup Analyses**

We further performed a meta-analysis on the association between apathy and different conversion outcomes. The pooled estimates showed that apathy could increase the risk of developing MCI (OR = 3.38, 95% CI: 1.57–7.28,  $I^2 = 71\%$ ) and dementia (OR = 2.12, 95% CI: 1.32–3.41,  $I^2 = 86\%$ ) (**Figure 3**). For one study with cognitive decline defined as  $\geq$  3-point reduction in

Mini-Mental State Examination (MMSE) scores, this subgroup did not show significance (OR = 1.27, 95% CI: 0.81–2.00,  $I^2 = 64\%$ ) (15). For the HR meta-analysis, in the MCI and dementia subgroups, the combined HRs were also significant (HR = 1.98, 95% CI: 1.44–2.73,  $I^2 = 0\%$ ; HR = 3.42, 95% CI: 1.13–10.32,  $I^2 = 97\%$ , respectively). For other subgroup analyses (**Figure 4**), OR meta-analysis results suggested that the association between

				Odds Ratio	Odds Ratio
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Acosta et al.2018	0.4132	0.2859	10.9%	1.51 [0.86, 2.65]	
Burke et al.2016	1.3484	0.137	13.5%	3.85 [2.94, 5.04]	
Clarke et al. 2010(1)	0.5008	0.2258	12.0%	1.65 [1.06, 2.57]	
Clarke et al. 2010(2)	0.0392	0.15	13.2%	1.04 [0.76, 1.42]	+
Geda et al.2014	0.8468	0.2742	11.1%	2.33 [1.36, 3.99]	
Krell Roesch et al.2020	1.6292	0.3205	10.2%	5.10 [2.71, 9.61]	
Tau Ming Liew.2020	0.8324	0.1353	13.5%	2.30 [1.76, 3.00]	
Van Dalen et al.2018	0.2868	0.1598	13.2%	1.33 [0.97, 1.82]	-
Van der Linde et al. 2013	0.9736	1.1305	2.3%	2.65 [0.29, 24.27]	
<b>Total (95% CI)</b> Heterogeneity: Tau² = 0.25; Test for overall effect: Z = 3	Chi² = 57.43, df = .85 (P = 0.0001)	8 (P < 0.	<b>100.0%</b> 00001); l²	<b>2.07 [1.43, 2.99]</b> = 86%	0.05 0.2 1 5 20 Favours [NCI] Favours [CI]
				Hazard Patio	Hazard Patio
Study or Subgroup	a[Hazard Ratio]	SE	Weight	IV Pandom 95% CI	IV Random 95% Cl
Burke et al 2016	2 2528	0 3053	18 5%	0 51 15 23 17 311	
Ceïde et al. 2010	0 1917	0.3033	10.3%		
Geda et al 2014	0.4347	0.2070	20.1%	2 25 [1 49 3 41]	
Masters et al 2015	1 3376	0.159	20.1%	3 81 [2 79 5 20]	
Van Dalen et al 2018	0 1858	0.0948	21.4%	1 20 [1 00 1 45]	-
Van Balon et al.2010	0.1000	0.0010	21.170	1.20 [1.00, 1.10]	
Total (95% CI)			100.0%	2.70 [1.38, 5.27]	
Heterogeneity: Tau <sup>2</sup> = 0.54 Test for overall effect: Z = 2	; Chi² = 71.02, df = 2.91 (P = 0.004)	= 4 (P < (	0.00001);	l² = 94%	0.05 0.2 1 5 20 Favours [NCI] Favours [CI]
FIGURE 3   Value of apathy in the p	rediction of different	outcomes	expressed	as odds ratios and hazar	rd ratios.

apathy and cognitive impairment was enhanced in the clinical sample (OR = 2.97, 95% CI: 1.79-4.93) when the percentage of females was lower than 60% (OR = 2.42, 95% CI: 1.20-4.87) and when neuropsychiatric inventory (NPI) measurements were used (OR = 2.75, 95% CI: 1.91-3.97). The outcome assessment criteria did not result in significant differences. A longer followup did not show significance (OR = 1.40, 95% CI: 0.95-2.06). HR subgroup analyses showed similar results. There was no significant difference when longer follow-up times were used (HR = 1.60, 95% CI: 0.87-2.96). There was no significant difference when the age was <75 years (HR = 3.22, 95% CI: 0.44– 25.11). ApoE status adjustment did not result in a significantly different outcome. The apathy measurement and depression adjustment subgroups involved the same research, and the use of the Geriatric Depression Scale (GDS) and adjustment for depression showed only a tendency (HR = 1.28, 95% CI: 1.01-1.63, P = 0.05).

#### **Risk of Publication Bias**

Egger's tests for the OR and HR meta-analyses did not show publication bias (t = 0.05, p = 0.96; t = 0.46, p = 0.67, respectively). The funnel plots can be found in **Supplementary Figures 4**, **5** of the supplemental documents.

## DISCUSSION

The primary outcome of this meta-analysis revealed that apathy was associated with a greater than 2-fold increased risk of

incident cognitive impairment. However, unlike the previous meta-analysis (9), our systematic review included cohort studies comprising cognitively intact community samples. Compared with previous studies, our study conducted the OR and HR analyses separately. Both analyses generated similar results and thus confirmed the association between apathy and cognitive impairment. Besides, the subgroup analyses per sampling settings, the sex distribution, age, and ApoE genotyping status further consolidated the findings of our study. Therefore, it might extend the results in a more generalizable manner to the broader older population.

The results support the hypothesis that apathy is predominantly prodromal to cognitive impairment among those in the normal cognitive population. The predictive value was diminished with longer follow-up times. It is plausible to hypothesize that apathy-associated patterns of dementiarelated atrophy start at the stage of normal cognitive function. Apathy has been closely associated with components of the frontostriatal circuit (19, 20). The frontostriatal circuit, linking the ventral striatum to the dorsal anterior cingulate cortex (ACC) via the ventral pallidum and thalamus, is crucially involved in effort-based decision making and executive functions (20). Apathy has been confirmed to be substantially associated with executive function deterioration (21). Apathy could also contribute to cognitive impairment by driving metabolic abnormalities (22). The Alzheimer's Disease Neuroimaging Initiative (ADNI) study demonstrated a correlation between posterior cingulate cortex (PCC)

		T				
Constantio (95%CI)						
Cinical comple	2	860/				2 07 [1 70 4 02]
Concern sample	7	749/				2.97 [1.79, 4.93]
Ser	7	/4/0				1.77 [1.25, 2.57]
Sex	5	000/	I _			1 00 [1 16 2 11]
<u>&lt;00%</u>	3	90%		-		1.90 [1.10, 3.11]
<00%	4	80%				2.42 [1.20, 4.87]
ronow up	(	769/	I _			
<5 >5	0	/0%				2.37 [1.75, 3.77]
	3	0970	-			1.40 [0.95, 2.06]
Apainy measurement	5	750/	I _			2 75 [1 01 2 07]
NPI	5	75%				2.75 [1.91, 3.97]
Others	4	12%	<b> </b> ■-			1.28 [1.03, 1.59]
Outcome assessment	-	0.604				
DSM/NINCDS	5	86%		_		2.12 [1.32, 3.41]
Others	4	86%				2.04 [1.09, 3.81]
Hazard Ratio(95%C	1)					
Age			L _			
≥75	2	0%		_		1.98 [1.44, 2.73]
<75	2	98% -		-		3.22 [0.44, 25.13]
Follow up				_		
<5	3	90%		_		3.85 [1.67, 8.87]
≥5	2	86%				1.60 [0.87, 2.96]
Adjust depression			I_			
Adjusting	2	21%	<b> </b> ■-	_		1.28 [1.01, 1.63]
Not adjusting	3	87%	I -			4.19 [2.13, 8.25]
Adjust ApoE			1		_	
Adjusting	2	86%	I			5.80 [2.37,14.17]
Not adjusting	3	75%				1.59 [1.05, 2.41]
Apathy measurement						
NPI	3	87%				4.19 [2.13, 8.25]
GDS	2	21%	<b>-</b>			1.28 [1.01, 1.63]
		0.00	2 00	4 00	6.00	

hypometabolism and higher apathy scores (23). Subgroups of studies showed that apathy has the highest impact among the oldest population. The older population is more often due to neurodegenerative processes, which provides more evidence for apathy more likely to be a prodromal syndrome in the CN population.

In this meta-analysis, apathy could predict both MCI and dementia but not cognitive decline as measured by MMSE scores, suggesting that apathy may be less helpful in predicting cognitive change below the MCI threshold. It is reasonable that higher predictions could be obtained in clinical samples than in general community-dwelling older populations, as clinical samples might have much more severe conditions than the general population. Regarding the other results of our subgroup analysis, there was not much difference based on ApoE adjustment, suggesting that apathy could independently predict cognitive impairment regardless of ApoE genetic status. A previous meta-analysis also showed no association between APOE carriership and the presence of apathy (24).

Apathy was hard to differentiate from depression in the cognitively normal population. Apathy is characterized by decreased salience-related processing in the anterior cingulate cortex, whereas depression is characterized by increased salience-related processing (25). The two syndromes also differ on a neurochemical basis. Apathy may be associated with cholinergic deficits. However, depression may be associated with serotoninergic deficits or a dopamine-norepinephrine imbalance (26). In our study, we did not find an association after depression adjustment. However, the depression adjustment subgroup contained only two articles, and both used a depression-specific scale, which might lack sensitivity for detecting apathy. Besides, apathy is not easy to evaluate or detect, as it has three different domains. The variability of symptoms across domains may

complicate the assessment. Most studies used NPI or scale of depression to evaluate neuropsychiatric syndromes, which are not specific for detecting apathy. Therefore, in future research, more work is warranted to confirm the association of apathy and cognitive impairment after adjusting for depressive symptoms and using more sensitive apathy measurements with specific tools, such as apathy evaluation scaly (AES) or Apathy Motivation Index in the general population (27).

#### LIMITATIONS

Our review has some limitations. First, the value of apathy in predicting cognitive impairment development was verified, but the heterogeneity was high. We thus performed subgroup analyses to try to identify sources of heterogeneity. Second, subgroup analyses explained how some characteristics influenced the association between apathy and cognitive impairment, but the number of studies in each subgroup, such as depression adjustment status, was limited. Therefore, the results should be cautiously interpreted. Third, most studies in this metaanalysis used the NPI or GDS. However, these are validated scales; they are not specifically designed for measuring apathy, as is the apathy evaluation scale, which might have diluted the associations. Last, our study only conducted a comprehensive search of the major electronic English databases but did not include unpublished data, gray literature, and those published in other languages. Thus, the likelihood of a publication bias might exist. Further studies should consider these factors.

#### CONCLUSIONS

In conclusion, this meta-analysis adds to previous evidence regarding apathy as a significant risky mental state for MCI

#### REFERENCES

- Krell-Roesch J, Syrjanen JA, Mielke MM, Christianson TJ, Kremers WK, Machulda MM, et al. Association between neuropsychiatric symptoms and functional change in older non-demented adults: mayo clinic study of aging. J Alzheimers Dis. (2020) 78:911–7. doi: 10.3233/JAD-200764
- Brodaty H, Heffernan M, Draper B, Reppermund S, Kochan NA, Slavin MJ, et al. Neuropsychiatric symptoms in older people with and without cognitive impairment. J Alzheimers Dis. (2012) 31:411–20. doi: 10.3233/JAD-2012-120169
- 3. Liew TM. Symptom clusters of neuropsychiatric symptoms in mild cognitive impairment and their comparative risks of dementia: a cohort study of 8530 older persons. *J Am Med Dir Assoc.* (2019) 20:1054. doi: 10.1016/j.jamda.2019.02.012
- 4. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-alzheimer's association workgroups on diagnostic guidelines for alzheimer's disease. *Alzheimers Dement.* (2011) 7:280–92. doi: 10.1016/j.jalz.2011.03.003
- Geda YE, Roberts RO, Knopman DS, Petersen RC, Christianson TJH, Pankratz VS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging. *Arch Gen Psychiatry*. (2008) 65:1193– 8. doi: 10.1001/archpsyc.65.10.1193
- 6. Robert P, Lanctôt KL, Agüera-Ortiz L, Aalten P, Bremond F, Defrancesco M, et al. Is it time to revise the diagnostic criteria for apathy in brain

and dementia for those in the general population. The findings support the concept of mild behavioral impairment as a prodromal syndrome to dementia (28). Older people with apathy were less likely to engage in social activities and were less motivated to seek clinicians' assistance; they were very vulnerable to cognitive impairment. In future research, more sensitive measurements are needed to detect apathy symptoms in the general population. In addition, more research is needed to clarify whether the association between apathy and conversion to cognitive impairment changed with adjustments for confounding variables.

### **AUTHOR CONTRIBUTIONS**

ZF and LW contributed to the study extraction, data analysis, and drafted the manuscript. XL and HZ made some comments. CY, LT, YZ, and MZ provided some suggestions on how to revise the paper. XY and HW contributed to the design of this study, interpretation of data, and critical revision of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

#### FUNDING

This work was funded by China's National Key R&D Program (XY, Grant Number: 2018YFC1314200; HW, Grant Number: 2017YFC1311100).

#### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt. 2021.792168/full#supplementary-material

disorders? the 2018 international consensus group. Eur Psychiatry. (2018) 54:71-6. doi: 10.1016/j.eurpsy.2018.07.008

- Huang S-S, Lee M-C, Liao Y-C, Wang W-F, Lai T-J. Caregiver burden associated with behavioral and psychological symptoms of dementia (BPSD) in Taiwanese elderly. *Arch Gerontol Geriatr.* (2012) 55:55–9. doi: 10.1016/j.archger.2011.04.009
- Saari T, Hallikainen I, Hintsa T, Koivisto AM. Neuropsychiatric symptoms and activities of daily living in Alzheimer's disease: ALSOVA 5-year follow-up study. *Int Psychogeriatrics*. (2020) 32:741–51. doi: 10.1017/S1041610219001571
- van Dalen JW, van Wanrooij LL, Moll van Charante EP, Brayne C, van Gool WA, Richard E. Association of apathy with risk of incident dementia. *JAMA Psychiatry*. (2018) 75:1012. doi: 10.1001/jamapsychiatry.2018.1877
- Acosta I, Borges G, Aguirre-Hernandez R, Sosa AL, Prince M. Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: a 10/66 dementia research group study. *Alzheimers Dement.* (2018) 14:271–9. doi: 10.1016/j.jalz.2017. 08.015
- Ceïde ME, Warhit A, Ayers EI, Kennedy G, Verghese J. Apathy and the risk of predementia syndromes in community-dwelling older adults. J Gerontol Ser B. (2020) 75:1443–50. doi: 10.1093/geronb/gbaa063
- Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJH, Pankratz VS, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. *Am J Psychiatry.* (2014) 171:572–81. doi: 10.1176/appi.ajp.2014.13060821

- Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) For Assessing The Quality If Nonrandomized Studies In Meta-Analyses. (2012). Available online at: http://www.ohri.ca/ programs/clinical\_epidemiology/oxford.asp
- van der Linde RM, Stephan BCM, Matthews FE, Brayne C, Savva GM. The presence of behavioural and psychological symptoms and progression to dementia in the cognitively impaired older population. *Int J Geriatr Psychiatry*. (2013) 28:700–9. doi: 10.1002/gps.3873
- Clarke DE, Ko JY, Lyketsos C, Rebok GW, Eaton WW. Apathy and cognitive and functional decline in community-dwelling older adults: results from the Baltimore ECA longitudinal study. *Int Psychogeriatrics*. (2010) 22:819–29. doi: 10.1017/S1041610209991402
- Liew TM. Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia. *Alzheimers Res Ther.* (2020) 12:35. doi: 10.1186/s13195-020-00604-7
- Burke SL, Maramaldi P, Cadet T, Kukull W. Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. *Arch Gerontol Geriatr.* (2016) 65:231–8. doi: 10.1016/j.archger.2016.04.006
- Masters MC, Morris JC, Roe CM. "Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis. *Neurology*. (2015) 84:617–22. doi: 10.1212/WNL.00000000001238
- Le Heron C, Apps MAJ, Husain M. The anatomy of apathy: a neurocognitive framework for amotivated behaviour. *Neuropsychologia.* (2018) 118:54–67. doi: 10.1016/j.neuropsychologia.2017.07.003
- Nobis L, Husain M. Apathy in Alzheimer's disease. Curr Opin Behav Sci. (2018) 22:7–13. doi: 10.1016/j.cobeha.2017.12.007
- Kawagoe T, Onoda K, Yamaguchi S. Apathy and executive function in healthy elderly—resting state fMRI study. *Front Aging Neurosci.* (2017) 9:124. doi: 10.3389/fnagi.2017.00124
- Ng KP, Chiew HJ, Rosa-Neto P, Kandiah N, Ismail Z, Gauthier S. Brain metabolic dysfunction in early neuropsychiatric symptoms of dementia. *Front Pharmacol.* (2019) 10:1–8. doi: 10.3389/fphar.2019.01398
- Gatchel JR, Donovan NJ, Locascio JJ, Becker JA, Rentz DM, Sperling RA, et al. Regional 18F-fluorodeoxyglucose hypometabolism is associated with higher apathy scores over time in early alzheimer disease. *Am J Geriatr Psychiatry*. (2017) 25:683–93. doi: 10.1016/j.jagp.2016.12.017

- Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P. Apolipoprotein E and affective symptoms in mild cognitive impairment and Alzheimer's disease dementia: a systematic review and meta-analysis. *Neurosci Biobehav Rev.* (2019) 96:302–15. doi: 10.1016/j.neubiorev.2018.11.020
- Onoda K, Yamaguchi S. Dissociative contributions of the anterior cingulate cortex to apathy and depression: topological evidence from resting-state functional MRI. *Neuropsychologia.* (2015) 77:10–8. doi: 10.1016/j.neuropsychologia.2015.07.030
- Mortby ME, Maercker A, Forstmeier S. Apathy: a separate syndrome from depression in dementia? a critical review. *Aging Clin Exp Res.* (2012) 24:305– 16. doi: 10.3275/8105
- Klar VS, Ang Y, Lockwood P, Attaallah B, Dickson S, Drew D, et al. Assessment of apathy in neurological patients using the apathy motivation index caregiver version. *J Neuropsychol.* (2021). doi: 10.1111/jnp.12262. [Epub ahead of print].
- Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z, et al. Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. *Am J Geriatr Psychiatry*. (2019) 27:823–34. doi: 10.1016/j.jagp.2019.01.215

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Fan, Wang, Zhang, Lv, Tu, Zhang, Zhang, Yan, Yu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.